Patient characteristics and response to treatment according to P2RY8-CRLF2 fusion in 268 patients with childhood BCP-ALL
| . | P2RY8-CRLF2 . | P2RY8-CRLF2 + . | ||||
|---|---|---|---|---|---|---|
| Positive . | Negative . | P . | Major sub/clone* . | Minor subclone* . | P . | |
| No. of patients (%) | 67 (25.0) | 201 (75.0) | 18 (6.7) | 49 (18.3) | ||
| Sex (%) | .724 | .974 | ||||
| Male | 37 (55.2) | 106 (52.7) | 10 (55.6) | 27 (55.1) | ||
| Female | 30 (44.8) | 95 (47.3) | 8 (44.4) | 22 (44.9) | ||
| Age, y (%) | .003 | .11 | ||||
| 1-10 | 55 (82.1) | 126 (62.7) | 17 (94.4) | 38 (77.6) | ||
| ≥ 10 | 12 (17.9) | 75 (37.3) | 1 (5.6) | 11 (22.4) | ||
| WBC count (%) | .561 | .872 | ||||
| < 50 000/μL | 55 (82.1) | 171 (85.1) | 15 (83.3) | 40 (81.6) | ||
| ≥ 50 000/μL | 12 (17.9) | 30 (14.9) | 3 (16.7) | 9 (18.4) | ||
| Pred response (%) | .279 | .796 | ||||
| Good | 64 (95.5) | 183 (91.0) | 17 (94.4) | 47 (95.9) | ||
| Poor | 3 (4.5) | 17 (8.5) | 1 (5.6) | 2 (4.1) | ||
| Not available | 0 (0.0) | 1 (0.5) | 0 (0.0) | 0 (0.0) | ||
| Treatment arm (%) | .343 | .671 | ||||
| Standard risk | 19 (28.4) | 39 (19.4) | 6 (33.3) | 13 (26.6) | ||
| Intermediate risk | 39 (58.2) | 129 (64.2) | 11 (61.1) | 28 (57.1) | ||
| High risk | 7 (10.4) | 29 (14.4) | 1 (5.6) | 6 (12.2) | ||
| Death before risk stratification | 2 (3.0) | 3 (1.5) | 0 (0.0) | 2 (4.1) | ||
| Other | 0 (0.0) | 1 (0.5) | 0 (0.0) | 0 (0.0) | ||
| DS (%) | < .001 | .009 | ||||
| Yes | 15 (22.4) | 5 (2.5) | 8 (44.4) | 7 (14.3) | ||
| No | 52 (77.6) | 196 (97.5) | 10 (55.6) | 42 (85.7) | ||
| Relapse (%) | .006 | .137 | ||||
| Yes | 16 (23.9) | 21 (10.4) | 2 (11.1) | 14 (28.6) | ||
| No | 51 (76.1) | 180 (89.6) | 16 (88.9) | 35 (71.4) | ||
| Incidence of relapse non-DS cases (CIR)† (%) | 13/52 (35 ± 8) | 21/196 (13 ± 3) | .008 | 2/10 (38 ± 21) | 11/42 (35 ± 9) | .825 |
| Standard risk | 2/13 (24 ± 15) | 2/37 (7 ± 5) | .216 | 0/3 | 2/10 (24 ± 15) | .739 |
| Intermediate risk | 9/31 (38 ± 10) | 14/127 (13 ± 4) | .015 | 2/6 (40 ± 22) | 7/25 (38 ± 12) | .855 |
| High risk | 2/7 (50 ± 25) | 5/28 (22 ± 9) | .540 | 0/1 (0) | 2/6 (50 ± 25) | n.a. |
| Median follow-up, y (range) | 5.1 (1.1-10.9) | 5.2 (1.1-10.6) | n.a. | 5.4 (1.5-9.8) | 5.1 (1.1-10.9) | n.a. |
| . | P2RY8-CRLF2 . | P2RY8-CRLF2 + . | ||||
|---|---|---|---|---|---|---|
| Positive . | Negative . | P . | Major sub/clone* . | Minor subclone* . | P . | |
| No. of patients (%) | 67 (25.0) | 201 (75.0) | 18 (6.7) | 49 (18.3) | ||
| Sex (%) | .724 | .974 | ||||
| Male | 37 (55.2) | 106 (52.7) | 10 (55.6) | 27 (55.1) | ||
| Female | 30 (44.8) | 95 (47.3) | 8 (44.4) | 22 (44.9) | ||
| Age, y (%) | .003 | .11 | ||||
| 1-10 | 55 (82.1) | 126 (62.7) | 17 (94.4) | 38 (77.6) | ||
| ≥ 10 | 12 (17.9) | 75 (37.3) | 1 (5.6) | 11 (22.4) | ||
| WBC count (%) | .561 | .872 | ||||
| < 50 000/μL | 55 (82.1) | 171 (85.1) | 15 (83.3) | 40 (81.6) | ||
| ≥ 50 000/μL | 12 (17.9) | 30 (14.9) | 3 (16.7) | 9 (18.4) | ||
| Pred response (%) | .279 | .796 | ||||
| Good | 64 (95.5) | 183 (91.0) | 17 (94.4) | 47 (95.9) | ||
| Poor | 3 (4.5) | 17 (8.5) | 1 (5.6) | 2 (4.1) | ||
| Not available | 0 (0.0) | 1 (0.5) | 0 (0.0) | 0 (0.0) | ||
| Treatment arm (%) | .343 | .671 | ||||
| Standard risk | 19 (28.4) | 39 (19.4) | 6 (33.3) | 13 (26.6) | ||
| Intermediate risk | 39 (58.2) | 129 (64.2) | 11 (61.1) | 28 (57.1) | ||
| High risk | 7 (10.4) | 29 (14.4) | 1 (5.6) | 6 (12.2) | ||
| Death before risk stratification | 2 (3.0) | 3 (1.5) | 0 (0.0) | 2 (4.1) | ||
| Other | 0 (0.0) | 1 (0.5) | 0 (0.0) | 0 (0.0) | ||
| DS (%) | < .001 | .009 | ||||
| Yes | 15 (22.4) | 5 (2.5) | 8 (44.4) | 7 (14.3) | ||
| No | 52 (77.6) | 196 (97.5) | 10 (55.6) | 42 (85.7) | ||
| Relapse (%) | .006 | .137 | ||||
| Yes | 16 (23.9) | 21 (10.4) | 2 (11.1) | 14 (28.6) | ||
| No | 51 (76.1) | 180 (89.6) | 16 (88.9) | 35 (71.4) | ||
| Incidence of relapse non-DS cases (CIR)† (%) | 13/52 (35 ± 8) | 21/196 (13 ± 3) | .008 | 2/10 (38 ± 21) | 11/42 (35 ± 9) | .825 |
| Standard risk | 2/13 (24 ± 15) | 2/37 (7 ± 5) | .216 | 0/3 | 2/10 (24 ± 15) | .739 |
| Intermediate risk | 9/31 (38 ± 10) | 14/127 (13 ± 4) | .015 | 2/6 (40 ± 22) | 7/25 (38 ± 12) | .855 |
| High risk | 2/7 (50 ± 25) | 5/28 (22 ± 9) | .540 | 0/1 (0) | 2/6 (50 ± 25) | n.a. |
| Median follow-up, y (range) | 5.1 (1.1-10.9) | 5.2 (1.1-10.6) | n.a. | 5.4 (1.5-9.8) | 5.1 (1.1-10.9) | n.a. |